ClinicalTrials.gg

Program

ataciguat

Also written as “ataciguat (HMR1766)” and “Ataciguat”.

Its studies are mostly in Aortic Valve Stenosis · Intermittent Claudication · Pain, led by 2 companies.

Furthest: phase 3, since Mar 2, 20073 company-led studies, 1 open or runningNext primary completion: Aug 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi20 open or runningphase 2since Mar 2, 2007Mar 2, 2007none ahead
Kardigan11 open or runningphase 3since May 13, 2025May 13, 2025Aug 31, 2028phase 3 · NCT07001800

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2007First study: phase 2 study in Intermittent ClaudicationNew to SanofiSanofi · NCT00443287 · 553 enrolled · United States, Austria, Canada and more
  2. Nov 27, 2008Phase 2 study in PainSanofi · NCT00799656 · 62 enrolled · Austria, Czech Republic, Romania
  3. May 13, 2025Kardigan's first study: phase 3 study in Aortic Valve StenosisNew to KardiganKardigan · NCT07001800 · 1,276 planned · United States, Canada

Ahead

  1. Aug 31, 2028Primary completion: phase 3 study in Aortic Valve StenosisKardigan · NCT07001800

TargetBeta

“Soluble guanylate cyclase activator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
Nitroglycerinrulemediquest-therapeuticsphase 414
praliciguatruleIronwood Pharmaceuticalsphase 28

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07001800Aortic Valve Stenosis · United States, Canada3RecruitingKardiganAug 31, 20281,276
NCT00799656Pain · Austria, Czech Republic, Romania2CompletedSanofiJun 200962
NCT00443287Intermittent Claudication · United States, Austria, Canada and more2CompletedSanofiOct 2008553

How it is read

Names in the registry

  • “ataciguat (HMR1766)”, 2 entries
  • “Ataciguat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.